Growth stalls at 10%, margins hold; recovery in early innings
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade C
Q1 FY'27 grew 11.8%, Q2 grew 10%; both miss the 20-25% CAGR pace. Guidance pending on new platforms.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Vimta is executing defensively: Q2 revenue grew 10% YoY (vs 20-25% prior target) due to external R&D slowdown and Middle East export headwinds, not operational failure. EBITDA margins held at 35.5%, PAT up only 3.5%. Multiple growth platforms (biologics, CRADS, preclinical) are early/undercapitalized. Risk: if external headwinds persist and new platforms don't scale in next 2-3 quarters, FY'28 ₹700 Cr guidance becomes unachievable.
₹112 Cr
Revenue · +10% YoY₹20.6 Cr
Reported PAT · +3.5% YoYFlat
Margins · vs guidance: OverstatedDid the claims hold up?
Revenue growth down due to external R&D pipeline, export headwinds
METQ2 revenue ₹112 Cr, YoY +10% vs prior 20-25% CAGR target; H1 grew 11.8%
Biologics revenue started in Q2, very early stage
METMD confirmed revenue generation begun Q2, currently 'very modest', early discussions with customers
Preclinical business CAGR ~30% last 4 years, one of strongest services
METMD stated 'CAGR of almost 30% in this business' over last 4 years
Margin improvement possible with volume growth and service-mix shift
OVERSTATEDQ2 EBITDA margin 35.5% flat vs H1 FY'26 at 36%, margin correction risk 100-200 bps possible due to biologics mix shift
NFL (food) samples at 70% recovery levels
METMD said operating 'around maybe 70%, 60% to 70%' of normal levels after Middle East war impact
Earnings quality
What changed since the last call
Revenue growth deceleration acknowledged
DowngradePrior Q1 guidance/target: 20-25% CAGR FY'27. Delivered: Q1 11.8%, Q2 10% growth. External factors (R&D slowdown, export headwinds) cited.
Biologics commercialized
UpgradeQ2 milestone: revenue generation begun from biologics (INR25 Cr capex invested). Still very early, multiple customers in active discussions.
Margin trajectory hedged
DowngradePrior: margins to stabilize with volume growth. Now: 100-200 bps correction possible due to service-mix shift toward biologics; reiterates 35-36% medium-term target but with headwind caveat.
Capex utilization delayed
NeutralINR100 Cr building capex (post-COVID) completed but underutilized post-COVID. Biologics new capex INR25 Cr onstream but no revenue at scale yet.
The Q&A
Analysts pressed hard on growth miss and capex ROI. MD remained defensive: blamed external R&D slowdown and export headwinds, not operations. On capex returns, acknowledged 5-7 year payback on infrastructure, 3+ years for biologics. Held ground on margin guidance but conceded 100-200 bps downside risk. Overall: deflective but coherent.
Growth slowdown root cause — Aditya Chheda, InCred Asset Management
AnsweredReasons are external, not Vimta's ability. R&D pipeline on pharma side slow. Export headwinds from Middle East war. Inquiries picking up, optimistic on conversion near-term. Strength of portfolio diversity allows handling headwinds.
Preclinical business growth — Madhuri Rane, MR Capital
AnsweredPreclinical is one of largest growth drivers. CAGR of almost 30% in last 4 years. Strongest service for us right now.
Biologics order pipeline — Madhuri Rane, MR Capital
AnsweredAlready working on initial order booked. Talking to multiple clients, hope to onboard couple more this quarter. 2-3 years for significant contribution. Cross-selling opportunity with existing clients.
NFL sample recovery — Madhuri Rane, MR Capital
AnsweredDefinitely better vs April/July when operating ~30-40% of normal. Now operating 70%, 60-70% of normal. Recovery improving, room still to come back to earlier volumes.
Margin sustainability — Renga Varshini, Wealthfiled
PartialMay not see shift in significant manner near-term. Medium-term: possibility of correction 100-200 bps. More to do with service-mix (biologics has lower margins initially) than cost headwinds. Manpower costs up but offset by efficiency.
Employee productivity and cost — Rupesh, Long Equity Partners
PartialFlat headcount is good indicator when revenue moving up. Goal to stay flat while improving productivity. New technologies (AI, biosimulation, advanced models) will help. FTE <5%. Employee cost offset unlikely to decline but can stay disciplined.
Capex utilization and ROI — Rupesh, Long Equity Partners
AnsweredINR100 Cr is infrastructure for 5-7 year capacity. Post-COVID, started building. Now space for expansion. Biologics INR25 Cr invested; 1:1 return expected in 3 years, maybe 2 if faster. Equipment normally 1:1 return year-over-year. New capability capex takes time with incubation period.
Clinical research capacity — Rohan Shah, RS Investment
AnsweredCurrently 180 beds capacity constraint. Lost some major clients last year. Now diversifying contracts for multiple customers. Recovery 12-18 months in, funnel conversion expected. Delta investment minimal; mostly contracting multiples.
Electronics testing capacity — Rohan Shah, RS Investment
AnsweredGrowing at decent pace. Can do better but small business component. 70-80% capacity used by defense OEM. Electronics exports ~39% this year. Domestic manufacturing deepening. Volumes not like pharma/food but margins nice.
Pharma Analytics revenue concentration — Vishal Manchanda, Systematix Institutional Equities
DodgedClient concentration changes Q-Q. Ranges 25-35% top 5. Long-term relationships but project-wise orders. Overseas clients higher value, different nature. Large molecules (biosimilars/biologics) future focus.
CRADS biologics capex and investment — Vishal Manchanda, Systematix Institutional Equities
PartialINR20 Cr invested so far. 1:1 return goal. Too early to quantify exact timeline, but 1:1 return on investment expected. Reactors capacity constraint just hit in H1; expanding. Delta investment ongoing for customer growth.
FY'28 revenue and margin guidance confirmation — Sagar Shah, Financial Research
AnsweredYes.
Guidance
FY'28 ₹700 Cr (implying ₹560-600 Cr FY'27 base if 20-25% CAGR holds)
MediumConfirmed on call when asked directly. Dependent on R&D pipeline recovery, export headwind easing, biologics/CRADS conversion. Not explicitly stated FY'27 number, implying slippage risk.
EBITDA margin 35-36% medium-term (FY'28+)
MediumReaffirmed but hedged: 100-200 bps correction possible due to service-mix shift toward lower-margin biologics early-stage. Manpower cost rising but offset by efficiency. No specific margin target for FY'27.
FY'27 ₹80 Cr capex (₹10 Cr biologics, ₹70 Cr routine maintenance/expansion)
HighOn track; H1 spent ₹112-115 Cr suggesting full-year will exceed guidance. Biologics expansion tied to customer wins. INR100 Cr post-COVID infrastructure now fully operational.
Risks the call surfaced
Growth slowdown materiality
HighQ2 revenue +10% YoY vs 20-25% CAGR target. If slowdown extends beyond H2, FY'27/FY'28 guidance at risk. R&D pipeline and export headwinds unresolved.
Capex ROI and utilization
HighINR100 Cr post-COVID infrastructure capex complete but underutilized. INR25 Cr biologics capex onstream but no revenue at scale; 1:1 return expected in 3 years = 3-4 year payback. Biologics customer wins critical.
Margin compression from service-mix shift
MediumBiologics initially lower-margin business (acknowledged by management). Early-stage revenue contribution could compress EBITDA margin by 100-200 bps. Management hedged on margin trajectory.
Clinical research customer concentration
MediumClinical research segment lost major clients last year, now 180-bed capacity constraint. Recovery dependent on successful customer conversion 12-18 months in. Single-customer loss risk material.
External headwinds unresolved
MediumR&D pharma pipeline slowdown (not Vimta-specific but industry-wide) and Middle East export war impact on food testing both ongoing. No visibility on resolution timeline.
Management
Score 7/10. Transparent on challenges and timelines (2-3 years for biologics scale, 5-7 years for infrastructure capex). Avoided specifics on Pharma Analytics customer concentration (25-35% range, project-wise not disclosed). Defensive but coherent on growth slowdown attribution to external factors. Track record mixed: Q1-Q2 FY'27 grew 11.8% and 10% vs 20-25% CAGR target; margins held at 35.5-36%. Post-COVID infrastructure capex INR100 Cr now complete and yielding capacity. Biologics commercialization milestone achieved (Q2 revenue start). Preclinical business CAGR ~30% over 4 years—strongest discipline.
1 · Q3-Q4 FY'27
CRADS improvement from R&D pipeline recovery, multiple customers onboarded
2 · Q3 FY'27
Biologics: onboard 2+ customers, revenue traction begins
3 · H2 FY'27
Food/NFL export samples recover from Middle East war impact
Risk: if external headwinds persist and new platforms don't scale in next 2-3 quarters, FY'28 ₹700 Cr guidance becomes unachievable.
Vimta Labs Q2 FY27 (standalone): PAT grows just 3% YoY as depreciation outpaces revenue
PAT +3.48% YoY · revenue +9.95% · margins compressing
₹111.98 Cr
+9.95% YoY
₹20.61 Cr
+3.48% YoY
17.94%
-1.1pp YoY
₹4.61
Vimta Labs' standalone revenue from operations rose 9.95% YoY to ₹111.98 Cr (+2.67% QoQ from ₹109.07 Cr), but net profit grew just 3.48% YoY to ₹20.61 Cr and actually slipped 2.03% QoQ from ₹21.04 Cr — a clear case of profit growth lagging topline growth rather than tracking it. No formal Q2-specific street consensus was found (the result was approved and filed same-day, 30 October 2026), but analyst FY27 full-year revenue consensus sits at ₹470.8 Cr, itself below management's own ₹500 Cr (20-25% CAGR) target set on the Q1 call. Measured against that guidance, this quarter falls short again: revenue growth of 9.95% YoY (H1 FY27 growth is 10.85% YoY on ₹221.06 Cr) remains well under the guided range, continuing the shortfall management itself flagged after Q1 ("11.8% revenue growth, below target").
Q2 FY-2027 vs prior quarters
The margin story is the real driver of the soft bottom line. EBITDA-level margin held up at 33.82% of revenue, roughly flat against 33.61% a year ago (though down from 34.21% in Q1), so the operating business is not the problem. The squeeze sits below that line: depreciation & amortisation jumped 25.66% YoY to ₹12.87 Cr (from ₹10.24 Cr), consistent with the ₹80 Cr FY27 capex programme (₹70 Cr routine, ₹10 Cr biologics) management guided, dragging PBT growth down to 4.76% YoY despite the steady EBITDA margin. A higher effective tax rate (25.11% vs 24.19% a year ago) then widened the gap further, leaving PAT growth of 3.48% YoY — half the pace of revenue growth. Net profit margin accordingly compressed to 17.95% from 19.06% YoY (-111 bps).
The stock went into the print at ₹498.35, down 15.7% over the past month of trading.
For context: revenue is at a 6-quarter high.
Targeting ₹500 Cr FY27 (20-25% CAGR); Q1 delivered 11.8% revenue growth, below target. ₹80 Cr capex planned (₹10 Cr biologics, ₹70 Cr routine). Expects margins to stabilize with volume growth.
— This quarter: missed
On corporate developments, the Board used this meeting to formally note the incorporation of Vimta Labs LLC, the wholly-owned US subsidiary first flagged in a May 2026 intimation — an early step in the company's stated US expansion, with no revenue or cost impact visible yet in these numbers. Separately, the August 2026 cybersecurity incident disclosure ("operations unaffected") is borne out by this quarter's numbers showing no disruption. No standalone management press release accompanied this filing in our records, so there is no company commentary to cross-check against the print beyond the board outcome letter itself.
W1
Whether H2 FY27 revenue accelerates enough to close the gap to management's ₹500 Cr / 20-25% CAGR FY27 target — H1 run-rate of ₹221.06 Cr implies only ~10.85% YoY growth so far
W2
Depreciation and NPM trajectory as the remaining ~₹53 Cr of the ₹80 Cr FY27 capex plan capitalises — D&A already +25.66% YoY this quarter
W3
Early cost/revenue contribution from newly incorporated Vimta Labs LLC (US subsidiary) in coming quarters
Standalone-only filing (company has no subsidiary/associate/JV this quarter); source figures in ₹ millions converted to Crore; no exceptional items in Q2 FY27 or the year-ago quarter (FY26's ₹1.62 Cr labour-code exceptional was booked only in the full year, not any quarter).